Free Trial

Taysha Gene Therapies (NASDAQ:TSHA) Given "Buy" Rating at Needham & Company LLC

Taysha Gene Therapies logo with Medical background

Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA - Free Report) in a research note released on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $8.00 price objective on the stock.

Several other research firms have also issued reports on TSHA. JMP Securities increased their target price on Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a research note on Thursday, May 29th. Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Canaccord Genuity Group raised their price objective on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, June 3rd. Chardan Capital lifted their price objective on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Taysha Gene Therapies in a research note on Thursday, May 29th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $8.20.

Get Our Latest Report on Taysha Gene Therapies

Taysha Gene Therapies Trading Down 1.2%

Shares of TSHA stock traded down $0.03 during trading hours on Tuesday, hitting $2.40. The company had a trading volume of 726,725 shares, compared to its average volume of 2,924,120. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.35 and a quick ratio of 5.35. The stock has a market capitalization of $515.18 million, a PE ratio of -7.06 and a beta of 0.97. The company's fifty day moving average is $2.50 and its 200 day moving average is $1.92. Taysha Gene Therapies has a fifty-two week low of $1.05 and a fifty-two week high of $3.31.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). Taysha Gene Therapies had a negative return on equity of 104.93% and a negative net margin of 1,201.08%. The company had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. During the same quarter in the previous year, the company earned ($0.10) earnings per share. Research analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Paul B. Manning purchased 750,000 shares of Taysha Gene Therapies stock in a transaction on Friday, May 30th. The shares were bought at an average price of $2.75 per share, with a total value of $2,062,500.00. Following the transaction, the insider directly owned 2,841,704 shares of the company's stock, valued at approximately $7,814,686. This trade represents a 35.86% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.78% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently made changes to their positions in TSHA. Ground Swell Capital LLC acquired a new stake in Taysha Gene Therapies in the fourth quarter valued at approximately $25,000. Cibc World Markets Corp purchased a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at approximately $28,000. E Fund Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at approximately $31,000. Hsbc Holdings PLC raised its holdings in shares of Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after purchasing an additional 8,076 shares in the last quarter. Finally, AXQ Capital LP acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at $39,000. 77.70% of the stock is owned by institutional investors and hedge funds.

About Taysha Gene Therapies

(Get Free Report)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Recommended Stories

Analyst Recommendations for Taysha Gene Therapies (NASDAQ:TSHA)

Should You Invest $1,000 in Taysha Gene Therapies Right Now?

Before you consider Taysha Gene Therapies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.

While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines